Market Overview

Pain Therapeutics Gains 7%, FDA Has Accepted Company's Remoxy For Review


Shares of Pain Therapeutics, Inc. (NASDAQ: PTIE), a micro-cap biopharmaceutical company whose lead drug candidate, REMOXY, is used for the treatment of moderate to severe pain.

Pain Therapeutics announced after Tuesday's market close the U.S. Food and Drug Administration determined that its New Drug Application (NDA) re-submission for Remoxy is sufficiently complete to permit a substantive review.

Pain Therapeutics added that the FDA has set September 25, 2016 as a target action date under the Prescription Drug User Fee Act (PDUFA).

"The acceptance of the REMOXY NDA marks another important milestone for Pain Therapeutics," said Remi Barbier, President and Chief Executive Officer of Pain Therapeutics. "We are grateful to the people, partners and patient investors who are helping to make this innovation a reality. We look forward to working closely with the FDA during the regulatory review process."

Posted-In: Biopharmaceutical Companies New Drug Application PDUFA Remi Barbier RemoxyNews FDA


Related Articles (PTIE)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Comtech Telecommunications' Unit Gets $1.3 Million Contract

Delphi Offers Long-Term Outlook, Reports New $1.5 Billion Buyback Plan